Designer interface peptide grafts target estrogen receptor alpha dimerization.

ABSTRACT: The nuclear transcription factor estrogen receptor alpha (ER?), triggered by its cognate ligand estrogen, regulates a variety of cellular signaling events. ER? is expressed in 70% of breast cancers and is a widely validated target for anti-breast cancer drug discovery. Administration of anti-estrogen to block estrogen receptor activation is still a viable anti-breast cancer treatment option but anti-estrogen resistance has been a significant bottle-neck. Dimerization of estrogen receptor is required for ER activation. Blocking ER? dimerization is therefore a complementary and alternative strategy to combat anti-estrogen resistance. Dimer interface peptide "I-box" derived from ER residues 503-518 specifically blocks ER dimerization. Recently using a comprehensive molecular simulation we studied the interaction dynamics of ER? LBDs in a homo-dimer. Based on this study, we identified three interface recognition peptide motifs LDKITDT (ER? residues 479-485), LQQQHQRLAQ (residues 497-506), and LSHIRHMSNK (residues 511-520) and reported the suitability of using LQQQHQRLAQ (ER 497-506) as a template to design inhibitors of ER? dimerization. Stability and self-aggregation of peptide based therapeutics poses a significant bottle-neck to proceed further. In this study utilizing peptide grafted to preserve their pharmacophoric recognition motif and assessed their stability and potential to block ER? mediated activity in silico and in vitro. The Grafted peptides blocked ER? mediated cell proliferation and viability of breast cancer cells but did not alter their apoptotic fate. We believe the structural clues identified in this study can be used to identify novel peptidometics and small molecules that specifically target ER dimer interface generating a new breed of anti-cancer agents.

SUBMITTER: Chakraborty S 

PROVIDER: S-EPMC5214063 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature